UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 19, 2015
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation)
333-174853 | 20-1515998 |
(Commission File Number) | (I.R.S. Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
(Registrant's telephone number, including area code)
_________________________________________________
(Former name, former address and former fiscal year, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions.
[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR240.14d-2(b))
[_] Soliciting material pursuant to Rule 14a-12 under Exchange Act (17 CFR240.14a-12)
[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))
[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR240.13e-4(c))
SECTION 5. CORPORATE GOVERNANCE AND MANAGEMENT
Item 5.01 Changes in Control of Registrant
On November 19, 2015, Nutritional Health Institute Laboratories, LLC ("NHIL"), the Company's largest shareholder, entered into a Plan of Merger with Biovaccine, Inc., a Florida corporation ("Biovaccine"), and World Health Solutions, LLC, a Florida limited liability company ("WHS"). The separate existence and organization of NHIL and Biovaccine ceased upon the Effective Date and World Health Solutions, LLC is the surviving party. World Health Solutions, LLC is the majority shareholder of the Company, owning approximately 81% of the Company's issued and outstanding common stock.
SECTION 8. OTHER EVENTS
Item 8.01 Other Events
On December 3, 2015, the Court of Appeals rejected the Company's appeal of the SEC suspension from October 2014 regarding the trading suspension of Global Green, Inc. stock.
SECTION 9. FINANCIAL STATEMENTS AND EXHIBITS
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. The following is a complete list of exhibits filed as part of this Report. Exhibit numbers correspond to the numbers in the exhibit table of Item 601 of Regulation S-K.
Exhibit No. | Description |
99.1 | Articles of Organization - World Health Solutions, LLC |
99.2 | Plan of Merger |
99.3 | Articles of Merger |
-1-
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
GLOBAL GREEN, INC.
(Registrant)
Date: December 31, 2015
/s/ Dr. Mehran P. Ghazvini______________
Dr. Mehran P. Ghazvini, President and CEO
-2-
